Therapeutic Effects of Angiotensin (AT1) Receptor Antagonists View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-11

AUTHORS

Boris Schmidt, Helmut Drexler, Bernhard Schieffer

ABSTRACT

Blockade of the renin-angiotensin system improves morbidity and mortality of patients with cardiovascular diseases, e. g. arterial hypertension, renal failure, following myocardial infarction and in congestive heart failure. The angiotensin II type 1 (AT1) receptor antagonists (angiotensin receptor blockers; ARBs), i. e. losartan, eprosartan, irbesartan and valsartan were developed by computer-based molecule design. Early observations already indicate that the ARBs elicit pleiotropic effects developing anti-aggregatory, anti-inflammatory and anti-mitogenic effects independent from their actions at the AT1 receptor. Losartan metabolism indicates a number of known active intermediates and pointed to further interactions of these derivatives with other receptors and cellular signaling systems. Here we discuss a compilation of detailed pharmacokinetic and pharmacodynamic data of active metabolites of ARBs indicating their mode of action and suggest novel therapeutic implications. The clinical observations that ARBs elicit potencies in patients with cardiovascular diseases via the regulation of inflammatory, growth and homeostatic factors lead us to focus on specific, reactive metabolites, which hold potential for future indications and possible drug interactions in cardiovascular diseases. More... »

PAGES

361-368

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00129784-200404060-00004

DOI

http://dx.doi.org/10.2165/00129784-200404060-00004

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046653147

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15554721


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "3',5'-Cyclic-AMP Phosphodiesterases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Human Growth Hormone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renin-Angiotensin System", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute for Organic Chemistry, Technische Universit\u00e4t Darmstadt, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6546.1", 
          "name": [
            "Institute for Organic Chemistry, Technische Universit\u00e4t Darmstadt, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schmidt", 
        "givenName": "Boris", 
        "id": "sg:person.011536612622.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011536612622.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology and Angiology, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10423.34", 
          "name": [
            "Department of Cardiology and Angiology, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Drexler", 
        "givenName": "Helmut", 
        "id": "sg:person.010063330502.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010063330502.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology and Angiology, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10423.34", 
          "name": [
            "Department of Cardiology and Angiology, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schieffer", 
        "givenName": "Bernhard", 
        "id": "sg:person.01075113266.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075113266.30"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00003495-199855050-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013303459", 
          "https://doi.org/10.2165/00003495-199855050-00011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s0009-9236(97)90080-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000047472", 
          "https://doi.org/10.1016/s0009-9236(97)90080-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00123662", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041311966", 
          "https://doi.org/10.1007/bf00123662"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280050405", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006948037", 
          "https://doi.org/10.1007/s002280050405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s0009-9236(97)90120-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034979080", 
          "https://doi.org/10.1016/s0009-9236(97)90120-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-11", 
    "datePublishedReg": "2004-11-01", 
    "description": "Blockade of the renin-angiotensin system improves morbidity and mortality of patients with cardiovascular diseases, e. g. arterial hypertension, renal failure, following myocardial infarction and in congestive heart failure. The angiotensin II type 1 (AT1) receptor antagonists (angiotensin receptor blockers; ARBs), i. e. losartan, eprosartan, irbesartan and valsartan were developed by computer-based molecule design. Early observations already indicate that the ARBs elicit pleiotropic effects developing anti-aggregatory, anti-inflammatory and anti-mitogenic effects independent from their actions at the AT1 receptor. Losartan metabolism indicates a number of known active intermediates and pointed to further interactions of these derivatives with other receptors and cellular signaling systems. Here we discuss a compilation of detailed pharmacokinetic and pharmacodynamic data of active metabolites of ARBs indicating their mode of action and suggest novel therapeutic implications. The clinical observations that ARBs elicit potencies in patients with cardiovascular diseases via the regulation of inflammatory, growth and homeostatic factors lead us to focus on specific, reactive metabolites, which hold potential for future indications and possible drug interactions in cardiovascular diseases.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00129784-200404060-00004", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1024601", 
        "issn": [
          "1175-3277", 
          "1179-187X"
        ], 
        "name": "American Journal of Cardiovascular Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "keywords": [
      "cardiovascular disease", 
      "receptor antagonist", 
      "angiotensin II type 1 receptor antagonist", 
      "type 1 receptor antagonist", 
      "mortality of patients", 
      "renin-angiotensin system", 
      "angiotensin receptor antagonists", 
      "congestive heart failure", 
      "possible drug interactions", 
      "anti-mitogenic effect", 
      "novel therapeutic implications", 
      "losartan metabolism", 
      "arterial hypertension", 
      "renal failure", 
      "heart failure", 
      "AT1 receptor", 
      "myocardial infarction", 
      "drug interactions", 
      "therapeutic effect", 
      "pharmacodynamic data", 
      "therapeutic implications", 
      "clinical observations", 
      "future indications", 
      "active metabolite", 
      "homeostatic factors", 
      "reactive metabolites", 
      "disease", 
      "mode of action", 
      "patients", 
      "antagonist", 
      "receptors", 
      "pleiotropic effects", 
      "metabolites", 
      "hypertension", 
      "morbidity", 
      "losartan", 
      "infarction", 
      "ARBs", 
      "failure", 
      "blockade", 
      "eprosartan", 
      "valsartan", 
      "mortality", 
      "irbesartan", 
      "cellular signaling systems", 
      "earlier observations", 
      "signaling system", 
      "effect", 
      "potency", 
      "metabolism", 
      "action", 
      "indications", 
      "factors", 
      "regulation", 
      "data", 
      "observations", 
      "number", 
      "potential", 
      "implications", 
      "interaction", 
      "growth", 
      "system", 
      "derivatives", 
      "further interaction", 
      "molecule design", 
      "design", 
      "intermediates", 
      "mode", 
      "active intermediates", 
      "compilation"
    ], 
    "name": "Therapeutic Effects of Angiotensin (AT1) Receptor Antagonists", 
    "pagination": "361-368", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046653147"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00129784-200404060-00004"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15554721"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00129784-200404060-00004", 
      "https://app.dimensions.ai/details/publication/pub.1046653147"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_380.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00129784-200404060-00004"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00129784-200404060-00004'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00129784-200404060-00004'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00129784-200404060-00004'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00129784-200404060-00004'


 

This table displays all metadata directly associated to this object as RDF triples.

212 TRIPLES      21 PREDICATES      112 URIs      98 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00129784-200404060-00004 schema:about N028f06828e724bf18fb92a3617ab3755
2 N1a0558e6286f4dacafbdab798f5bcce0
3 N22d74ec0634846a5b8a9939ce3111f72
4 N2488c7c82a894e9dbc0f16a6907ef762
5 N2bb5fa8bf45646c08fc6a2d5c374e7db
6 N666f33d35ac04fcf890082ac40963f9b
7 N7aadb909cca441a48dcd11a09830251f
8 Nd9f4fc99824c4d478de3dde75b1ceb46
9 Ne4839112a2734d979a96b901c31d0122
10 Nfcbb7c8854a448b0a3dfcce31121a4ae
11 anzsrc-for:11
12 anzsrc-for:1102
13 anzsrc-for:1115
14 schema:author Ncc5b85858a9e4664ad136cffc45742b1
15 schema:citation sg:pub.10.1007/bf00123662
16 sg:pub.10.1007/s002280050405
17 sg:pub.10.1016/s0009-9236(97)90080-1
18 sg:pub.10.1016/s0009-9236(97)90120-x
19 sg:pub.10.2165/00003495-199855050-00011
20 schema:datePublished 2004-11
21 schema:datePublishedReg 2004-11-01
22 schema:description Blockade of the renin-angiotensin system improves morbidity and mortality of patients with cardiovascular diseases, e. g. arterial hypertension, renal failure, following myocardial infarction and in congestive heart failure. The angiotensin II type 1 (AT1) receptor antagonists (angiotensin receptor blockers; ARBs), i. e. losartan, eprosartan, irbesartan and valsartan were developed by computer-based molecule design. Early observations already indicate that the ARBs elicit pleiotropic effects developing anti-aggregatory, anti-inflammatory and anti-mitogenic effects independent from their actions at the AT1 receptor. Losartan metabolism indicates a number of known active intermediates and pointed to further interactions of these derivatives with other receptors and cellular signaling systems. Here we discuss a compilation of detailed pharmacokinetic and pharmacodynamic data of active metabolites of ARBs indicating their mode of action and suggest novel therapeutic implications. The clinical observations that ARBs elicit potencies in patients with cardiovascular diseases via the regulation of inflammatory, growth and homeostatic factors lead us to focus on specific, reactive metabolites, which hold potential for future indications and possible drug interactions in cardiovascular diseases.
23 schema:genre article
24 schema:isAccessibleForFree false
25 schema:isPartOf N2ddd7a090f59414fa057458df1dd64cc
26 N37456983c1494431b2095591e732a5e5
27 sg:journal.1024601
28 schema:keywords ARBs
29 AT1 receptor
30 action
31 active intermediates
32 active metabolite
33 angiotensin II type 1 receptor antagonist
34 angiotensin receptor antagonists
35 antagonist
36 anti-mitogenic effect
37 arterial hypertension
38 blockade
39 cardiovascular disease
40 cellular signaling systems
41 clinical observations
42 compilation
43 congestive heart failure
44 data
45 derivatives
46 design
47 disease
48 drug interactions
49 earlier observations
50 effect
51 eprosartan
52 factors
53 failure
54 further interaction
55 future indications
56 growth
57 heart failure
58 homeostatic factors
59 hypertension
60 implications
61 indications
62 infarction
63 interaction
64 intermediates
65 irbesartan
66 losartan
67 losartan metabolism
68 metabolism
69 metabolites
70 mode
71 mode of action
72 molecule design
73 morbidity
74 mortality
75 mortality of patients
76 myocardial infarction
77 novel therapeutic implications
78 number
79 observations
80 patients
81 pharmacodynamic data
82 pleiotropic effects
83 possible drug interactions
84 potency
85 potential
86 reactive metabolites
87 receptor antagonist
88 receptors
89 regulation
90 renal failure
91 renin-angiotensin system
92 signaling system
93 system
94 therapeutic effect
95 therapeutic implications
96 type 1 receptor antagonist
97 valsartan
98 schema:name Therapeutic Effects of Angiotensin (AT1) Receptor Antagonists
99 schema:pagination 361-368
100 schema:productId N52d74b088fd94195b886e09e2f4336ee
101 N5c0208bad1f146c793229555e87508fb
102 Na2c95092289e480a92fd9f99eb8af321
103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046653147
104 https://doi.org/10.2165/00129784-200404060-00004
105 schema:sdDatePublished 2022-09-02T15:51
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher N6dca33aac2fb4e1a9515082473d77501
108 schema:url https://doi.org/10.2165/00129784-200404060-00004
109 sgo:license sg:explorer/license/
110 sgo:sdDataset articles
111 rdf:type schema:ScholarlyArticle
112 N028f06828e724bf18fb92a3617ab3755 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Human Growth Hormone
114 rdf:type schema:DefinedTerm
115 N1a0558e6286f4dacafbdab798f5bcce0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Cardiovascular Diseases
117 rdf:type schema:DefinedTerm
118 N22d74ec0634846a5b8a9939ce3111f72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Humans
120 rdf:type schema:DefinedTerm
121 N2488c7c82a894e9dbc0f16a6907ef762 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name 3',5'-Cyclic-AMP Phosphodiesterases
123 rdf:type schema:DefinedTerm
124 N25e2fab964a240089d2caeaf381a4597 rdf:first sg:person.010063330502.67
125 rdf:rest N3f13692ba8484db6936167ed5d4c1034
126 N2bb5fa8bf45646c08fc6a2d5c374e7db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Cyclooxygenase Inhibitors
128 rdf:type schema:DefinedTerm
129 N2ddd7a090f59414fa057458df1dd64cc schema:volumeNumber 4
130 rdf:type schema:PublicationVolume
131 N37456983c1494431b2095591e732a5e5 schema:issueNumber 6
132 rdf:type schema:PublicationIssue
133 N3f13692ba8484db6936167ed5d4c1034 rdf:first sg:person.01075113266.30
134 rdf:rest rdf:nil
135 N52d74b088fd94195b886e09e2f4336ee schema:name dimensions_id
136 schema:value pub.1046653147
137 rdf:type schema:PropertyValue
138 N5c0208bad1f146c793229555e87508fb schema:name doi
139 schema:value 10.2165/00129784-200404060-00004
140 rdf:type schema:PropertyValue
141 N666f33d35ac04fcf890082ac40963f9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Renin-Angiotensin System
143 rdf:type schema:DefinedTerm
144 N6dca33aac2fb4e1a9515082473d77501 schema:name Springer Nature - SN SciGraph project
145 rdf:type schema:Organization
146 N7aadb909cca441a48dcd11a09830251f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Recombinant Proteins
148 rdf:type schema:DefinedTerm
149 Na2c95092289e480a92fd9f99eb8af321 schema:name pubmed_id
150 schema:value 15554721
151 rdf:type schema:PropertyValue
152 Ncc5b85858a9e4664ad136cffc45742b1 rdf:first sg:person.011536612622.23
153 rdf:rest N25e2fab964a240089d2caeaf381a4597
154 Nd9f4fc99824c4d478de3dde75b1ceb46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Clinical Trials as Topic
156 rdf:type schema:DefinedTerm
157 Ne4839112a2734d979a96b901c31d0122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Animals
159 rdf:type schema:DefinedTerm
160 Nfcbb7c8854a448b0a3dfcce31121a4ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Angiotensin II Type 1 Receptor Blockers
162 rdf:type schema:DefinedTerm
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
167 schema:name Cardiorespiratory Medicine and Haematology
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
170 schema:name Pharmacology and Pharmaceutical Sciences
171 rdf:type schema:DefinedTerm
172 sg:journal.1024601 schema:issn 1175-3277
173 1179-187X
174 schema:name American Journal of Cardiovascular Drugs
175 schema:publisher Springer Nature
176 rdf:type schema:Periodical
177 sg:person.010063330502.67 schema:affiliation grid-institutes:grid.10423.34
178 schema:familyName Drexler
179 schema:givenName Helmut
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010063330502.67
181 rdf:type schema:Person
182 sg:person.01075113266.30 schema:affiliation grid-institutes:grid.10423.34
183 schema:familyName Schieffer
184 schema:givenName Bernhard
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075113266.30
186 rdf:type schema:Person
187 sg:person.011536612622.23 schema:affiliation grid-institutes:grid.6546.1
188 schema:familyName Schmidt
189 schema:givenName Boris
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011536612622.23
191 rdf:type schema:Person
192 sg:pub.10.1007/bf00123662 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041311966
193 https://doi.org/10.1007/bf00123662
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/s002280050405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006948037
196 https://doi.org/10.1007/s002280050405
197 rdf:type schema:CreativeWork
198 sg:pub.10.1016/s0009-9236(97)90080-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000047472
199 https://doi.org/10.1016/s0009-9236(97)90080-1
200 rdf:type schema:CreativeWork
201 sg:pub.10.1016/s0009-9236(97)90120-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034979080
202 https://doi.org/10.1016/s0009-9236(97)90120-x
203 rdf:type schema:CreativeWork
204 sg:pub.10.2165/00003495-199855050-00011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013303459
205 https://doi.org/10.2165/00003495-199855050-00011
206 rdf:type schema:CreativeWork
207 grid-institutes:grid.10423.34 schema:alternateName Department of Cardiology and Angiology, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
208 schema:name Department of Cardiology and Angiology, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
209 rdf:type schema:Organization
210 grid-institutes:grid.6546.1 schema:alternateName Institute for Organic Chemistry, Technische Universität Darmstadt, Darmstadt, Germany
211 schema:name Institute for Organic Chemistry, Technische Universität Darmstadt, Darmstadt, Germany
212 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...